Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNDX Syndax Pharmaceuticals

Not Yet Opened 01-22 16:00:00 EST

20.79

+0.27

+1.32%

盘后20.80

+0.01+0.04%

19:45 EST

High21.02	Low20.25	Vol1.30M
Open20.48	D1 Closing20.52	Amplitude3.75%
Mkt Cap1.81B	Tradable Cap1.51B	Total Shares86.91M
T/O26.92M	T/O Rate1.78%	Tradable Shares72.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals","latestPrice":20.79,"timestamp":1769115600000,"preClose":20.52,"halted":0,"volume":1295285,"hourTrading":{"tag":"盘后","latestPrice":20.799,"preClose":20.79,"latestTime":"19:45 EST","volume":48974,"amount":1018119.32,"timestamp":1769129110839,"change":0.009,"changeRate":0.000433,"amplitude":0.011496},"delay":0,"changeRate":0.013157894736842085,"floatShares":72721425,"shares":86914838,"eps":-3.600392,"marketStatus":"Not Yet Opened","change":0.27,"latestTime":"01-22 16:00:00 EST","open":20.48,"high":21.02,"low":20.25,"amount":26920136.12516,"amplitude":0.037524,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.600392,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769158800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":20.52,"preHourTrading":{"tag":"盘前","latestPrice":20.83,"preClose":20.52,"latestTime":"08:44 EST","volume":240,"amount":4941.3,"timestamp":1769089474934,"change":0.31,"changeRate":0.015107,"amplitude":0.01462},"postHourTrading":{"tag":"盘后","latestPrice":20.799,"preClose":20.79,"latestTime":"19:45 EST","volume":48974,"amount":1018119.32,"timestamp":1769129110839,"change":0.009,"changeRate":0.000433,"amplitude":0.011496},"volumeRatio":1.148521,"impliedVol":0.6112,"impliedVolPercentile":0.34},"requestUrl":"/m/hq/s/SNDX/tweets","defaultTab":"tweets","newsList":[{"id":"1101924063","title":"Stock Track | Syndax Pharmaceuticals Plummets 5.20% Intraday Amid Conflicting Analyst Sentiments","url":"https://stock-news.laohu8.com/highlight/detail?id=1101924063","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101924063?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:40","pubTimestamp":1768315216,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (SNDX) saw its stock price drop sharply by 5.20% during Tuesday's intraday trading session. The decline comes as analysts expressed conflicting sentiments about the company's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SNDX"],"gpt_icon":0},{"id":"2603500200","title":"Syndax Pharmaceuticals: Strong Revuforj Momentum, Underappreciated Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2603500200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603500200?lang=en_us&edition=fundamental","pubTime":"2026-01-13 18:35","pubTimestamp":1768300534,"startTime":"0","endTime":"0","summary":"Analyst Jason Zemansky from Bank of America Securities maintained a Buy rating on Syndax Pharmaceuticals and keeping the price target at $27.00. Ja...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/syndax-pharmaceuticals-strong-revuforj-momentum-underappreciated-pipeline-catalysts-support-attractive-risk-reward-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/syndax-pharmaceuticals-strong-revuforj-momentum-underappreciated-pipeline-catalysts-support-attractive-risk-reward-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX"],"gpt_icon":0},{"id":"2602514195","title":"Syndax Pharmaceuticals to Present Business Updates at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514195","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514195?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:02","pubTimestamp":1768219324,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. The company's Chief Executive Officer, Michael Metzger, is scheduled to discuss recent business updates and financial results during a webcast presentation, which will be accessible through the Investor section of Syndax’s website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL1WNCtS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","SNDX","LU2095319765.USD","BK4588","SG9999014039.USD","BK4112","NDAQ","SG9999014005.SGD","IE00B64PRP62.GBP","BK4139","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2602651494","title":"Syndax Pharmaceuticals Reports Strong 2025 Revenue Growth and Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2602651494","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602651494?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219244,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9fWpv9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","SNDX","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014039.USD","SG9999014021.USD","LU0314104364.USD","BK4139","LU2210150020.SGD","IE00BKPKM429.USD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","BK4585"],"gpt_icon":0},{"id":"2602514485","title":"Syndax Pharmaceuticals : Ended 2025 With About$394 Million in Cash, Cash Equivalents and Marketable Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514485?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA5870JJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2602514432","title":"Syndax Pharmaceuticals Inc - Revuforj Net Revenue up 38% in Q4 2025 VS Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514432?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA5870JJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2602514492","title":"Press Release: Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514492","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514492?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219200,"startTime":"0","endTime":"0","summary":"-- Approximately $44 million and $125 million in preliminary  Revuforj  4Q25 and full year 2025 net revenue, respectively --. -- Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increase in Revuforj net revenue in 4Q25 vs. 3Q25 -. -- $56 million and $152 million in preliminary  Niktimvo  4Q25 and full year 2025 net revenue, respectively; Syndax will report its share of the Niktimvo net profit when it reports full year 2025 results --. -- Ended 2025 with approximately $394 million in cash, cash equivalents and marketable securities ; fully funded through profitability --. NEW YORK, Jan. 12, 2026  -- Syndax Pharmaceuticals , a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced preliminary, unaudited fourth quarter and full year 2025 financial results and provided additional business updates ahead of its presentation at the 44 Annual J.P. Morgan Healthcare conference.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","LU0882574139.USD","LU1720051108.HKD","LU1791710400.SGD","LU1732800096.USD","LU1363072403.SGD","LU0106261372.USD","HCSG","LU0234570918.USD","LU2023251221.USD","XBI","XLV","LU0320765646.SGD","LU1732799900.SGD","IE00BZ1G4Q59.USD","TM","LU1791710582.SGD","BK4137","LU0029874061.USD","LU1244550494.USD","LU0225283273.USD","BK4581","LU2111349929.HKD","BK4555","R","BK4504","LU1989772923.USD","BK4588","BK4516","LU2089283258.USD","LU1244550577.SGD","LU2271345857.HKD","LU0557290698.USD","BK4139","CR","LU1720051017.SGD","BK4534","BK4604","IE00BKVL7J92.USD","LABU","LU0158827948.USD","LU0098860793.USD","LU1244550221.USD","LU0158827781.USD","LU0528227936.USD","03160","LU0314104364.USD","SNDX","LU2089284900.SGD"],"gpt_icon":0},{"id":"2601870546","title":"Syndax Pharmaceuticals Inc - Co and Woda to Expand Access to Revuforj Outside U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2601870546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601870546?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:03","pubTimestamp":1767787399,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y801O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2601087059","title":"Syndax: Program Will Be Launched in Parts of Eurasia, Central and Southeast Europe, Israel, Middle East and Turkey, Latin America, and Africa","url":"https://stock-news.laohu8.com/highlight/detail?id=2601087059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601087059?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:03","pubTimestamp":1767787399,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y801O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2601334870","title":"Syndax Pharmaceuticals and WODA Launch Global Access Program for Revuforj","url":"https://stock-news.laohu8.com/highlight/detail?id=2601334870","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601334870?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787227,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. has announced a collaboration with the World Orphan Drug Alliance  to expand access to its menin inhibitor, Revuforj , through a Managed Access Program. This initiative will allow physicians in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa to prescribe Revuforj to eligible patients in regions where the drug is not yet commercially available. The program will be administered by WODA in accordance with local regulations and ethical standards, aiming to bridge the gap in access to innovative cancer treatments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL1hW6f8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4112","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","SNDX","LU2095319765.USD","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2601885714","title":"Syndax Announces Presentation at the 44TH Annual J.p. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885714?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA49SGCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2211815571.USD","LU2237443465.HKD","SNDX","LU2237443549.SGD","LU2746668974.SGD","LU2237443978.SGD","IE00BKDWB100.SGD","LU2756315318.SGD","LU0234572021.USD","LU1116320737.USD","LU1720051017.SGD","IE00BHPRN162.USD","LU0943347566.SGD","LU1670628061.USD","LU2746668461.USD","LU0971096721.USD","LU0320765646.SGD","LU1084165304.USD","LU1894683348.USD","LU2237443382.USD","LU1551013425.SGD","LU2054465674.USD","LU1145028129.USD","LU0211328371.USD","LU0787776722.HKD","LU1917777945.USD","LU1670627923.USD","LU0310799852.SGD","IE00BBT3K403.USD","LU0345769631.USD","LU2237443622.USD","LU2237443895.HKD","LU0170899867.USD","LU0345770993.USD","LU1162221912.USD","LU0265550359.USD","LU2430703251.USD","BK4588","IE00BFXG1179.USD","LU0640476718.USD","LU2592432038.USD","LU2756315664.SGD","LU0265550946.USD","IE00BYXW3230.USD","LU1548497426.USD","LU0345769128.USD","LU0882574139.USD","LU1032466523.USD","IE00BDRTCR15.USD","LU1366192091.USD"],"gpt_icon":0},{"id":"2592190533","title":"Syndax Pharmaceuticals Moves to Uncertificated Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592190533","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592190533?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:31","pubTimestamp":1766179866,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. has amended its bylaws to provide that, beginning December 18, 2025, all shares of the company’s capital stock will be issued solely in uncertificated form. Shares represented by certificates issued before this date will remain in certificated form until the certificates are surrendered to the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL7zxlSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2590349574","title":"Syndax Pharmaceuticals Price Target Maintained With a $56.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349574","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349574?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:05","pubTimestamp":1765285500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 08:05 ET (13:05 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"1167606675","title":"Syndax Reports Strong Data for AML Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1167606675","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167606675?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:52","pubTimestamp":1765209128,"startTime":"0","endTime":"0","summary":"Shares of clinical-stage biopharmaceutical company Syndax Pharmaceuticals (SNDX) fell 3.2% in early Monday trading. The company presented updated data for its revumenib combination therapy at the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","BK4139","SNDX","LU2463526074.USD","ASH"],"gpt_icon":0},{"id":"2589612337","title":"Syndax Reports Revumenib Achieves 92% Complete Remission Rate in Newly Diagnosed AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2589612337","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589612337?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:50","pubTimestamp":1765194615,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL55MDVr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014005.SGD","BK4112","LU0314104364.USD","BK4588","NDAQ","BK4139","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","SNDX","SG9999014013.SGD"],"gpt_icon":0},{"id":"2588021781","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588021781","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588021781?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:01","pubTimestamp":1764795660,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on Decembe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3199315/0/en/Syndax-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSQ","SQQQ","NQmain","SNDX","USJW.SI","USAW.SI","TSYW.SI","QLD",".IXIC","MNQmain","QID","TQQQ","NVIW.SI"],"gpt_icon":1},{"id":"2588065845","title":"Syndax Pharmaceuticals (SNDX): Evaluating Valuation After FDA Approval and NCCN Guideline Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2588065845","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588065845?lang=en_us&edition=fundamental","pubTime":"2025-12-03 03:23","pubTimestamp":1764703400,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (SNDX) is in the spotlight following a series of positive events, including expanded FDA approval for Revvvi Forge in relapse-refractory NPM1-mutated AML and inclusion in the NCCN guidelines. These developments could strengthen the company’s position with investors and in the broader treatment landscape.\nSee our latest analysis for Syndax Pharmaceuticals.\nAfter riding a wave of positive FDA and guideline news, Syndax’s share price has soared 39.56% in the past month and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-evaluating-valuation-after-fda-a-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/syndax-pharmaceuticals-sndx-evaluating-valuation-after-fda-a-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2588724763","title":"Syndax Pharmaceuticals CEO to Join Evercore Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724763?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590457,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET. The event will feature Michael A. Metzger, Chief Executive Officer, and a live webcast will be available in the Investor section of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLbxY9Fq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","BK4139","IE00B3QW5Z07.USD","SNDX","IE00BKPKM429.USD","BK4585","LU0314104364.USD","EVR","BK4127","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2585849802","title":"Syndax Pharmaceuticals Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2585849802","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585849802?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:47","pubTimestamp":1763995620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 09:47 ET (14:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2585696284","title":"Syndax price target raised to $35 from $22 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2585696284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585696284?lang=en_us&edition=fundamental","pubTime":"2025-11-24 19:35","pubTimestamp":1763984126,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Syndax (SNDX) to $35 from $22 and keeps an Overweight rating on the shares. The firm updated the company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-35-from-22-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/syndax-price-target-raised-to-35-from-22-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SNDX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0419},{"period":"3month","weight":0.5366},{"period":"6month","weight":1.1589},{"period":"1year","weight":0.485},{"period":"ytd","weight":-0.0105}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.041583},{"month":2,"riseRate":0.666667,"avgChangeRate":0.081651},{"month":3,"riseRate":0.555556,"avgChangeRate":0.051247},{"month":4,"riseRate":0.4,"avgChangeRate":0.014629},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019495},{"month":6,"riseRate":0.5,"avgChangeRate":-0.003538},{"month":7,"riseRate":0.6,"avgChangeRate":0.016261},{"month":8,"riseRate":0.6,"avgChangeRate":0.106119},{"month":9,"riseRate":0.5,"avgChangeRate":-0.031411},{"month":10,"riseRate":0.2,"avgChangeRate":-0.077781},{"month":11,"riseRate":0.6,"avgChangeRate":0.04592},{"month":12,"riseRate":0.5,"avgChangeRate":0.035938}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Syndax Pharmaceuticals,SNDX,Syndax Pharmaceuticals股票,Syndax Pharmaceuticals股票老虎,Syndax Pharmaceuticals股票老虎国际,Syndax Pharmaceuticals行情,Syndax Pharmaceuticals股票行情,Syndax Pharmaceuticals股价,Syndax Pharmaceuticals股市,Syndax Pharmaceuticals股票价格,Syndax Pharmaceuticals股票交易,Syndax Pharmaceuticals股票购买,Syndax Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}